Clinical Trial Update: RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization

View source ↗

Summary

The RESTORE study evaluating safety and treatment optimization for efalizumab (Raptiva) in plaque psoriasis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Plaque Psoriasis | Status: TERMINATED